Video

Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer

Author(s):

Ursula Matulonis, M.D.
Conference|SGO Annual Meeting on Women's Cancer

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

PARP inhibitors work by blocking the repair of DNA within cancer cells, which then allows other DNA repair molecules to target the broken DNA strand.

Related Videos
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short black hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of man with black hair.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Related Content
Image of radiation targeting cancer cells.
November 5th 2024

Common Prostate Cancer Radiation Questions Answered

Alex Biese
Expert answers to patients’ questions were offered as part of the CURE® Educated Patient® Prostate Cancer Summit.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of ovaries.
October 30th 2024

Current Treatment May Be Superior to Recentin In Ovarian Cancer

Spencer Feldman
Treatment containing Recentin demonstrated clinical benefits, but it proves worse than the current standard care treatment.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Illustration of a female reproductive system.
October 21st 2024

Avutometinib and Defactinib May Benefit Some with Ovarian Cancer

Alex Biese
Results from the RAMP 201 clinical trial are promising for patients with recurrent low-grade serous ovarian cancer.
Image of PSA test.
October 21st 2024

Rise in PSA Levels May Predict Treatment Response in Prostate Cancer

Spencer Feldman
The rate at which PSA rises after hormonal therapy for prostate cancer is a key factor in determining the effectiveness of the treatment.